Larimar Therapeutics (LRMR) Interest Expenses (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Interest Expenses came in at $30000.0 in Q4 2025, up 50.0% YoY from $20000.0 in Q4 2024, and down 97.47% on a QoQ basis from $1.2 million in Q3 2025.
Larimar Therapeutics (LRMR) Interest Expenses (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Interest Expenses data on file, last reported at $30000.0 in Q4 2025.
- Quarterly Interest Expenses rose 50.0% year-over-year to $30000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30000.0 (up 50.0% YoY) and the FY2025 annual result came in at $1.5 million, down 99.13% from the prior year.
- Interest Expenses eased to $30000.0 in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $141.8 million in Q4 2023 to a low of $20000.0 in Q4 2024.
- A 5-year average of $24.3 million and a median of $7.1 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses surged 719.81% — and 2024, when it slumped 99.99%.
- Tracing LRMR's Interest Expenses over 5 years: stood at $124.0 million in 2021, then grew by 5.5% to $130.8 million in 2022, then gained by 8.36% to $141.8 million in 2023, then tumbled by 99.99% to $20000.0 in 2024, then jumped by 50.0% to $30000.0 in 2025.
- The last three Interest Expenses figures came in at $30000.0 (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | 5.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Mn |
| Jun 30, 2026 | 5.93 Mn |
| Dec 31, 2025 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 1.19 Mn |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Mar 31, 2025 | 6.05 Mn |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 7.40 Mn |
| Sep 30, 2024 | 7.40 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Jun 30, 2024 | 9.80 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 141.77 Mn |
| Dec 31, 2023 | 141.77 Mn |